Evidence map›Paper›PMID 29476046›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2018

Prognostic Significance of Zinc Finger E-Box-Binding Homeobox Family in Glioblastoma.

Peng Chen, Hongxin Liu, Aiwu Hou, Xibo Sun, Bingxuan Li, Jianyi Niu, Lingling Hu

Open access · hybridAbstract read
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Peng ChenDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Hongxin LiuDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Aiwu HouDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Xibo SunDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Bingxuan LiDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Jianyi NiuDepartment of Neurology, Yidu Central Hospital of Weifang, Weifang, Shandong, China (mainland).
Lingling HuDepartment of Gynecology, Linyi People's Hospital, Linyi, Shandong, China (mainland).
Yidu Central Hospital of Weifang · CNLinyi People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Epithelial-mesenchymal transition (EMT) is an essential progress for tumor cell invasion to both epithelial and non-epithelial cancers, and zinc finger E-box-binding homeobox 1/2 (ZEB1/2) is a well-known promoter of EMT. In glioma cell lines, both ZEB1 and ZEB2 have been demonstrated to facilitate cancer cell proliferation and invasion with experiments in vitro. However, the clinical significance of ZEB1 and ZEB2 in glioblastoma (GBM) is still controversial. MATERIAL AND METHODS We detected the expression of ZEB1 and ZEB2 in 91 cases of GBM with immunohistochemistry and investigated the correlation between clinicopathological factors and ZEB family expression with Fisher test. By univariate analysis with Kaplan-Meier test, we explored the prognostic significance of ZEB1/2 expression and the clinicopathological factors in GBM. By multivariate analysis with the Cox regression model, we identified the independent prognostic factors in GBM. RESULTS The percentages of ZEB1 high expression and ZEB2 high expression were 31.9% (29/91) and 41.9% (36/91), respectively. High expression of ZEB2 was significantly associated with lower survival rate of GBM patients (P=0.001). ZEB2, lower KPS score (P=0.004), gross total resection (P<0.001) and higher Ki67 percentage (P=0.001) were notably correlated to worse prognosis of GBM. With multivariate analysis, high expression of ZEB2 was demonstrated to be an independent prognostic factor indicating unfavorable prognosis of GBM (P=0.001, HR=3.86, and 95%CI=1.61-9.23). CONCLUSIONS High expression of ZEB2 is an independent prognostic factor predicting unfavorable prognosis of GBM, indicating that ZEB2 or its downstream proteins may be potential drug targets of GBM therapy.

Indexed as

AdultAgedBiomarkers, TumorCell ProliferationEpithelial-Mesenchymal TransitionFemaleGlioblastomaHumansImmunohistochemistryMaleMiddle AgedPrognosisZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2Biomarkers, TumorZEB1 protein, humanZEB2 protein, humanZinc Finger E-box-Binding Homeobox 1Zinc Finger E-box Binding Homeobox 2

Identifiers

PMID29476046
PMCPMC5834914
OpenAlexW2788200616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.